Tag: U.K.
-
FDA Clears AI Heart Failure Detection System
The Food and Drug Administration authorized for marketing an algorithm-driven medical device for diagnosing a common, but difficult to detect, type of heart failure.
-
Sustained-Released Eye Treatment Company Raises $11.9M
A company creating extended-release delivery techniques for eye therapies is raising $11.9 million in its first venture funding round.
-
Biotech, M.D. Anderson Partner on Precision Drug Design
A company discovering therapies with artificial intelligence is partnering with M.D. Anderson Cancer Center on new small-molecule precision medicines.
-
Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors
Research with lab animals shows an experimental cancer vaccine generates immune-system cells that infiltrate solid tumors and reduce the tumor’s protective environment.
-
Trial Shows Antibody Neutralizes, Reduces HIV Virus
Results from a clinical trial show an experimental one-time antibody therapy, even at low doses, lowers levels of HIV virus in people living with the disease.
-
“Dark Genome” Drug Discoverer Gains $37M in Early Funds
19 Oct. 2022. A biotechnology enterprise discovering new drugs from non-protein coding regions of the genome is raising €37.5 million ($US 36.6 million) in venture funds. Nucleome Therapeutics Ltd. in Oxford, U.K. is a three year-old business spun-off from genetic research labs at University of Oxford medical school. Nucleome Therapeutics is seeking new treatments for…
-
Gut Microbes Shown to Detect Colorectal Cancer
An analysis of gut bacteria and blood samples from patients indicates changes in the microbiome can provide early warnings for colorectal cancer.
-
Univ. Labs Ink Licensing Deals for Covid-19 Tests
Two companies agreed to license technologies from academic labs in the U.S. and U.K. for developing faster and more sensitive at-home tests for Covid-19 infections.
-
Immune Disease Biotech Acquired in $405M Deal
A biotechnology developer of treatments for autoimmune disorders with checkpoint receptor proteins is acquired by drug maker Gilead Sciences.
-
GSK Acquires Advanced Vaccine Biotech in $3.3B Deal
Drug maker GSK is buying a biotechnology company developing vaccines for respiratory and infectious diseases that generate multiple immune responses.